Everand Logo

Welcome to Everand!

  • STAT

    Opinion: We need smart coronavirus testing, not just more testing

    "Testing is not a panacea" but intelligent application of #coronavirus testing will provide vital public health information needed to effectively fight this pandemic.
    by Farzad Mostashari and Ezekiel J. Emanuel Mar 24, 2020 5 minutes
    A medical personnel member takes samples from a woman at a drive-through coronavirus testing lab set up by a local community center in West Palm Beach, Fla.

    Despite three weeks of assurances, most Americans who have symptoms of Covid-19 still can’t get tested for SARS-CoV-2, the coronavirus that causes the disease. Last Friday, Sen. Brian Schatz (D-Hawaii) tweeted succinctly, “Hey where are the tests.”

    The hardest-hit states are rationing tests to health workers and those who have Covid-19 symptoms. The Trump administration, meanwhile, continuously reassures us that we are getting more and more testing out there.

    While increasing the number of tests is absolutely necessary, it is not sufficient. If we want to stop Covid-19, we must also focus on gathering other essential information as these tests are administered. There’s little value to getting a bunch of positive test results without being able to understand the clinical conditions of the individuals they came from, how they were exposed

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
    Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

    Related Books & Audiobooks